Reference intervals of urinary acute kidney injury (AKI) markers [IGFBP7] · [TIMP2] in apparently healthy subjects and chronic comorbid subjects without AKI

Clinica Chimica Acta

Volumn 452, Issue , 2016, Pages 32-37

  Chindarkar, Nandkishor S ^a   Chawla, Lakhmir S ^b   Straseski, Joely A ^c   Jortani, Saeed A ^d   Uettwiller Geiger, Denise ^e   Orr, Robert R ^f   Kellum, John A ^g   Fitzgerald, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c ARUP LABORATORIES   (United States)

^d University of Louisville School of Medicine   (United States)

^e Mather Hospital Northwell Health   (United States)

^f Phoenix Medical Group   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Cell cycle arrest; Insulin like growth factor binding protein 7 (IGFBP7); Nephrocheck; Reference interval; Tissue inhibitor of metalloproteinases 2 (TIMP 2)

Indexed keywords

BIOLOGICAL MARKER; PROTEIN IGFBP7; SOMATOMEDIN BINDING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; TIMP2 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CHRONIC PATIENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REFERENCE VALUE; CHRONIC DISEASE; FLUORESCENCE; IMMUNOASSAY; MIDDLE AGED; NORMAL HUMAN; URINE;

ACUTE KIDNEY INJURY; ADULT; AGED; BIOMARKERS; CHRONIC DISEASE; FEMALE; FLUORESCENCE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MIDDLE AGED; REFERENCE VALUES; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84946615744     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.10.029     Document Type: Article

References (40)

1. Bellomo R., Kellum J.A., Ronco C. Acute kidney injury. Lancet 2012, 380:756-766.
2. Chertow G.M., Burdick E., Honour M., Bonventre J.V., Bates D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 2005, 16:3365-3370.
3. Koyner J.L., Shaw A.D., Chawla L.S., Hoste E.A., Bihorac A., Kashani K., et al. Tissue inhibitor metalloproteinase-2 (TIMP-2) IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI. J. Am. Soc. Nephrol. 2015, 26:1747-1754.
4. Lewington A.J.P., Jorge Cerdá J., Ravindra L., Mehta R.L. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 2013, 84:457-467.
5. Meersch M., Schmidt C., VAN Aken H., Martens S., Rossaint J., Singbartl K., et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One 2014, 9.
6. Hoste E.A., McCullough P.A., Kashani K., Chawla L.S., Joannidis M., Shaw A.D., et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol. Dial. Transplant. 2014, 29:2054-2061.
7. Endre Z.H., Pickering J.W. Acute kidney injury: cell cycle arrest biomarkers win race for AKI diagnosis. Nat. Rev. Nephrol. 2014, 10:683-685.
8. Siew E.D., Ware L.B., Ikizler T.A. Biological markers of acute kidney injury. J. Am. Soc. Nephrol. 2011, 22:810-820.
9. Kashani K., Al-Khafaji A., Ardiles T., Artigas A., Bagshaw S.M., Bell M., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care 2013, 17:R25.
10. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012, 2:1-138. (Suppl.).
11. Bihorac A., Chawla L.S., Shaw A.D., Al-Khafaji A., Davison D.L., Demuth G.E., et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am. J. Respir. Crit. Care Med. 2014, 189:932-939.
12. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 1999, 20:761-787.
13. Sprenger C.C., Vail M.E., Evans K., Simurdak J., Plymate S.R. Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene 2002, 21:140-147.
14. Wilson H.M., Birnbaum R.S., Poot M., Quinn L.S., Swisshelm K. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 2002, 13:205-213.
15. Stetler-Stevenson W.G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 2008, 1:re6.
16. Price P.M., Safirstein R.L., Megyesi J. The cell cycle and acute kidney injury. Kidney Int. 2009, 76:604-613.
17. Boonstra J., Post J.A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004, 337:1-13.
18. Seo D.W., Li H., Qu C.K., Oh J., Kim Y.S., Diaz T., et al. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J. Biol. Chem. 2006, 281:3711-3721.
19. Jaeschke H. Mechanisms of liver injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G1083-G1088.
20. Yang L., Besschetnova T.Y., Brooks C.R., Shah J.V., Bonventre J.V. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 2010, 16:535-543. (1p following 143).
21. Chindarkar NS, Chawla LS, Straseski JA, Jortani SA, Uettwiller-Geiger D, Orr RR, Kellum JA, Fitzgerald RL. Demographic Data for Reference Range Determinations of Urinary Acute Kidney Injury (AKI) Markers [IGFBP7] [TIMP2]. (In press, Data in brief).
22. Haliski J. FDA Allows Marketing of the First Test to Assess Risk of Developing Acute Kidney Injury. (Last accessed July 1, 2015). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412910.htm.
23. Nephrocheck® Test Kit Package Insert, Astute Medical, Inc. (PN 300152, Rev E 2014/09/05).
24. Horowitz G.L. Establishment and use of Reference Values. Tietz Textbok of Clinical Chemistry and Molecular Diagnostics 2012, 95-118. Elsevier Saunders, St. Louis (MO). 5th ed. C.A. Burtis, E.R. Ashwood, D.E. Bruns (Eds.).
25. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. CLSI Document C28-A3 2008, (ISBN 1-56238-682-4). Third edition.
26. Zar J.H. Biostatistical Analysis 1999, Prentice Hall.
27. Team TRC R: A Language and Environment for Statistical Computing 2013.
28. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin. Chem. 1974, 20:1255-1270.
29. Bagshaw S.M., Bellomo R. Early diagnosis of acute kidney injury. Curr. Opin. Crit. Care 2007, 13:638-644.
30. Macedo E., Malhotra R., Claure-Del Granado R., Fedullo P., Mehta R.L. Defining urine output criterion for acute kidney injury in critically ill patients. Nephrol. Dial. Transplant. 2011, 26:509-515.
31. Uchino S. Creatinine. Curr. Opin. Crit. Care 2010, 16:562-567.
32. Tietz N.W., Shuey D.F., Wekstein D.R. Laboratory values in fit aging individuals-sexagenarians through centenarians. Clin. Chem. 1992, 38:1167-1185.
33. Ali T., Khan I., Simpson W., Prescott G., Townend J., Smith W., et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J. Am. Soc. Nephrol. 2007, 18:1292-1298.
34. Lafrance J.P., Djurdjev O., Levin A. Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. Nephrol. Dial. Transplant. 2010, 25:2203-2209.
35. Mishra J., Dent C., Tarabishi R., Mitsnefes M.M., Ma Q., Kelly C., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
36. Mishra J., Ma Q., Prada A., Mitsnefes M., Zahedi K., Yang J., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003, 14:2534-2543.
37. Cowland J.B., Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997, 45:17-23.
38. Borkham-Kamphorst E., Drews F., Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int. 2011, 31:656-665.
39. Sabbisetti V.S., Waikar S.S., Antoine D.J., Smiles A., Wang C., Ravisankar A., et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J. Am. Soc. Nephrol. 2014, 25:2177-2186.
40. Dinarello C.A., Novick D., Kim S., Kaplanski G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 2013, 4:1-10.